Journal articles on the topic 'Directors label'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Directors label.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
Groves, Bruce W., and Roy H. Olsson. "Response Rates to Surveys with Self-Addressed, Stamped Envelopes versus a Self-Addressed Label." Psychological Reports 86, no. 3_suppl (June 2000): 1226–28. http://dx.doi.org/10.2466/pr0.2000.86.3c.1226.
Full textGroves, Bruce W., and Roy H. Olsson. "Response Rates to Surveys with Self-Addressed, Stamped Envelopes versus a Self-Addressed Label." Psychological Reports 86, no. 3_part_2 (June 2000): 1226–28. http://dx.doi.org/10.1177/003329410008600327.2.
Full textGupta, Shveta, Joseph R. Stanek, and Sarah H. O'Brien. "Off-Label Utilization Trend for Recombinant Factor VIIa in Children's Hospitals in the United States." Blood 134, Supplement_1 (November 13, 2019): 2177. http://dx.doi.org/10.1182/blood-2019-126294.
Full textSonneveld, Pieter, Maria-Victoria Mateos, Adrián Alegre, Thierry Facon, Cyrille Hulin, Mahmoud Hashim, Talitha Vincken, Tobias Kampfenkel, Sarah Cote, and Philippe Moreau. "Impact of Modified Thalidomide Dosing in Bortezomib/Thalidomide/Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible: A Matching-Adjusted Indirect Comparison." Blood 134, Supplement_1 (November 13, 2019): 4739. http://dx.doi.org/10.1182/blood-2019-122775.
Full textBussel, James B., Michael D. Tarantino, Victor S. Blanchette, Ashok Raj, Jenny Despotovic, Donald Beam, John Roy, Xuena Wang, Bhakti Mehta, and Melissa Eisen. "Safety and Efficacy of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)." Blood 128, no. 22 (December 2, 2016): 3738. http://dx.doi.org/10.1182/blood.v128.22.3738.3738.
Full textBose, Prithviraj, David McCue, Nathan P. Wiederhold, Tapan M. Kadia, Gautam Borthakur, Farhad Ravandi, Musa Yilmaz, et al. "Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study." Blood 132, Supplement 1 (November 29, 2018): 2674. http://dx.doi.org/10.1182/blood-2018-99-111727.
Full textTarantino, Michael D., James B. Bussel, Amy Geddis, Michael F. Guerrera, Alan K. Ikeda, Kun Nie, and Melissa Eisen. "Safety and Efficacy Of Long-Term Open-Label Romiplostim Dosing In Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)." Blood 122, no. 21 (November 15, 2013): 3530. http://dx.doi.org/10.1182/blood.v122.21.3530.3530.
Full textKruse-Jarres, Rebecca, Michael U. Callaghan, Stacy E. Croteau, Victor Jimenez-Yuste, Liane Khoo, Ri Liesner, Tadashi Matsushita, et al. "Surgical Experience in Two Multicenter, Open-Label Phase 3 Studies of Emicizumab in Persons with Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2)." Blood 130, Suppl_1 (December 7, 2017): 89. http://dx.doi.org/10.1182/blood.v130.suppl_1.89.89.
Full textTarantino, Michael D., James B. Bussel, Victor S. Blanchette, Jenny M. Despotovic, Carolyn Bennett, Ashok Raj, Bronwyn Williams, et al. "Safety and Efficacy of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Pediatric Patients with Immune Thrombocytopenia (ITP)." Blood 126, no. 23 (December 3, 2015): 3467. http://dx.doi.org/10.1182/blood.v126.23.3467.3467.
Full textNamoglu, Esin C., Mitchell E. Hughes, Daniel J. Landsburg, Stephen J. Schuster, Jakub Svoboda, Elise A. Chong, James N. Gerson, Stefan K. Barta, and Sunita Dwivedy Nasta. "Clinical Outcomes of Non-Hodgkin Lymphoma Patients on Acalabrutinib Including Off-Label Utilization." Blood 134, Supplement_1 (November 13, 2019): 5261. http://dx.doi.org/10.1182/blood-2019-130039.
Full textGrainger, John, James B. Bussel, Nichola Cooper, Michael Tarantino, Victor Blanchette, Jenny Despotovic, Alexey Maschan, Nancy Carpenter, Melissa Eisen, and Bhakti Mehta. "A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)." Blood 128, no. 22 (December 2, 2016): 869. http://dx.doi.org/10.1182/blood.v128.22.869.869.
Full textChari, Ajai, Maria-Victoria Mateos, Niels WCJ van de Donk, Jonathan L. Kaufman, Philippe Moreau, Albert Oriol, Torben Plesner, et al. "Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)." Blood 132, Supplement 1 (November 29, 2018): 1995. http://dx.doi.org/10.1182/blood-2018-99-113590.
Full textKulasekararaj, Austin, Antonio M. Risitano, Jaroslaw P. Maciejewski, Rosario Notaro, Peter Browett, Jong-Wook Lee, Mingjun Huang, Michael Geffner, and Robert A. Brodsky. "A Phase 2 Open-Label Study of Danicopan (ACH-0144471) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy." Blood 134, Supplement_1 (November 13, 2019): 3514. http://dx.doi.org/10.1182/blood-2019-124748.
Full textCarroll, Brigid, Coral Ingley, and Kerr Inkson. "Boardthink: Exploring the discourses and mind-sets of directors." Journal of Management & Organization 23, no. 5 (August 14, 2017): 606–20. http://dx.doi.org/10.1017/jmo.2017.36.
Full textGhobrial, Irene M., Michael R. Savona, Ravi Vij, David S. Siegel, Ashraf Badros, Jonathan L. Kaufman, Noopur Raje, Andrzej Jakubowiak, Mihaela Obreja, and Jesus G. Berdeja. "Final Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Hematologic Malignancies." Blood 128, no. 22 (December 2, 2016): 2110. http://dx.doi.org/10.1182/blood.v128.22.2110.2110.
Full textChari, Ajai, Hareth Nahi, Maria-Victoria Mateos, Henk M. Lokhorst, Jonathan L. Kaufman, Philippe Moreau, Albert Oriol, et al. "Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study." Blood 130, Suppl_1 (December 7, 2017): 838. http://dx.doi.org/10.1182/blood.v130.suppl_1.838.838.
Full textMoreau, Philippe, Maria-Victoria Mateos, Joan Bladé, Lotfi Benboubker, Javier de la Rubia, Thierry Facon, Raymond L. Comenzo, et al. "An Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma." Blood 124, no. 21 (December 6, 2014): 176. http://dx.doi.org/10.1182/blood.v124.21.176.176.
Full textYoung, Guy, Robert F. Sidonio, Ri Liesner, Johannes Oldenburg, Tiffany Chang, Marianne Uguen, Christophe Dhalluin, et al. "HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors." Blood 130, Suppl_1 (December 7, 2017): 85. http://dx.doi.org/10.1182/blood.v130.suppl_1.85.85.
Full textClemens, Pamela L., Steven Xu, Melody Luo, Ajai Chari, Saad Z. Usmani, Maria-Victoria Mateos, Niels WCJ van de Donk, et al. "Pharmacokinetics (PK) of Subcutaneous Daratumumab in Patients with Relapsed or Refractory (RR) Multiple Myeloma (MM): Primary Clinical Pharmacology Analysis of the Open-Label, Multicenter, Phase 1b Study (PAVO)." Blood 132, Supplement 1 (November 29, 2018): 2006. http://dx.doi.org/10.1182/blood-2018-99-113161.
Full textGrainger, John, James B. Bussel, Michael D. Tarantino, Nichola Cooper, Donald Beam, Jenny M. Despotovic, Alexey A. Maschan, Kejia Wang, Melissa Jeanne Eisen, and Charles Bowers. "Updated Results from the Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)." Blood 134, Supplement_1 (November 13, 2019): 1095. http://dx.doi.org/10.1182/blood-2019-131241.
Full textUsmani, Saad Z., Hareth Nahi, Maria-Victoria Mateos, Henk M. Lokhorst, Ajai Chari, Jonathan L. Kaufman, Philippe Moreau, et al. "Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)." Blood 128, no. 22 (December 2, 2016): 1149. http://dx.doi.org/10.1182/blood.v128.22.1149.1149.
Full textBussel, James B., Michael D. Tarantino, Amy Geddis, Michael F. Guerrera, Alan K. Ikeda, Kun Nie, Janet Franklin, and Melissa Eisen. "Safety and Efficacy of Long-Term Open-Label Dosing of Romiplostim in Thrombocytopenic Pediatric Patients (Pts) with Immune Thrombocytopenia (ITP)." Blood 124, no. 21 (December 6, 2014): 4184. http://dx.doi.org/10.1182/blood.v124.21.4184.4184.
Full textJurczak, Wojciech, Pier Luigi Zinzani, Georg Hess, Gianluca Gaidano, Mariano Provencio, Zsolt Nagy, Tadeusz Robak, et al. "A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis." Blood 134, Supplement_1 (November 13, 2019): 4078. http://dx.doi.org/10.1182/blood-2019-124297.
Full textWitzig, Thomas E., Lubomir Sokol, Eric D. Jacobsen, Won-Seog Kim, Francine M. Foss, Ranjana H. Advani, Jose Maria Roncero Vidal, et al. "Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study." Blood 132, Supplement 1 (November 29, 2018): 2937. http://dx.doi.org/10.1182/blood-2018-99-116277.
Full textKeefe, Peter J., Margaret C. Morrissey, Catherine E. McGuinn, and James B. Bussel. "Randomized Double-Blind Study of Increasing Doses of Eltrombopag in Patients with Chronic ITP." Blood 126, no. 23 (December 3, 2015): 1057. http://dx.doi.org/10.1182/blood.v126.23.1057.1057.
Full textPerkins, Andrew Charles, Kate Burbury, Thomas Lehmann, David M. Ross, Andreas Reiter, Vikas Gupta, Claire Harrison, et al. "Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis." Blood 136, Supplement 1 (November 5, 2020): 52–53. http://dx.doi.org/10.1182/blood-2020-140408.
Full textMichel, Marc, Marco Ruggeri, Tomás José González-López, Stephane Cheze, Waleed Ghanima, Tor Henrik Anderson Tvedt, Mikael Ebbo, James B. Bussel, and Bertrand Godeau. "Safety and Efficacy of the Off-Label Use of Thrombopoietin Receptor Agonists for Immune Thrombocytopenia in Pregnancy: Results from a Multicentre Observational Study." Blood 134, Supplement_1 (November 13, 2019): 1081. http://dx.doi.org/10.1182/blood-2019-122595.
Full textVerstovsek, Srdan, Robert P. Hasserjian, Olga Pozdnyakova, Ivo Veletic, Ruben A. Mesa, Lynda Foltz, John Mascarenhas, et al. "PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study." Blood 132, Supplement 1 (November 29, 2018): 686. http://dx.doi.org/10.1182/blood-2018-99-115362.
Full textRibrag, Vincent, Julio C. Chavez, Jason B. Kaplan, Umberto Vitolo, Jason C. Chandler, Armando Santoro, Paolo Corradini, et al. "A Phase 1b, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma: CC-122-DLBCL-001." Blood 128, no. 22 (December 2, 2016): 1849. http://dx.doi.org/10.1182/blood.v128.22.1849.1849.
Full textStewart, A. Keith, S. Vincent Rajkumar, Meletios A. Dimopoulos, Tamás Masszi, Ivan Spicka, Albert Oriol, Roman Hájek, et al. "Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study." Blood 124, no. 21 (December 6, 2014): 79. http://dx.doi.org/10.1182/blood.v124.21.79.79.
Full textShapiro, Amy, Giancarlo Castaman, Katarina Cepo, Lone Hvitfeldt Poulsen, Christian Hollensen, Tadashi Matsushita, Guy Young, Silva Zupancic-Salek, and Victor Jimenez-Yuste. "Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial." Blood 134, Supplement_1 (November 13, 2019): 1139. http://dx.doi.org/10.1182/blood-2019-122809.
Full textPetter, Säwen, Pankaj Kumar Mandal, Derrick J. Rossi, and David Bryder. "Hematopoietic Stem Cells Are Active Contributors to Hematopoiesis in Steady State." Blood 128, no. 22 (December 2, 2016): 421. http://dx.doi.org/10.1182/blood.v128.22.421.421.
Full textGreenbaum, Laurence A., Yahsou Delmas, Fadi Fakhouri, John F. Kincaid, Christoph Licht, Enrico E. Minetti, Chris Mix, et al. "Eculizumab Prevents Thrombotic Microangiopathy: Long-Term Follow-up Study of Patients with Atypical Hemolytic Uremic Syndrome." Blood 126, no. 23 (December 3, 2015): 2252. http://dx.doi.org/10.1182/blood.v126.23.2252.2252.
Full textSaleh, Mansoor N., James B. Bussel, Abderrahim Khelif, Paul Burgess, Ali El-Ali, Anuja Roy, Victoria Barghout, Mei Sheng Duh, Kelly M. Grotzinger, and Abdulgabar Salama. "Improvements in Patient Health-Related Quality of Life (HRQoL) with Clinical Efficacy in Patients Treated with Eltrombopag: Final Results from the Long-Term, Open-Label Extend Study." Blood 128, no. 22 (December 2, 2016): 3742. http://dx.doi.org/10.1182/blood.v128.22.3742.3742.
Full textMoreau, Philippe, Cyrille Hulin, Sonja Zweegman, Yannan Hu, Bart Heeg, Mahmoud Hashim, Carla de Boer, et al. "Comparative Efficacy and Safety of Bortezomib, Thalidomide, and Dexamethasone (VTd) without and with Daratumumab (D-VTd) from Cassiopeia Versus Vtd from Pethema/GEM in Patients with Newly Diagnosed Multiple Myeloma Using Propensity Score Matching (PSM)." Blood 134, Supplement_1 (November 13, 2019): 4740. http://dx.doi.org/10.1182/blood-2019-123491.
Full textMascarenhas, John O., Moshe Talpaz, Vikas Gupta, Lynda M. Foltz, Michael R. Savona, Ron Paquette, Robert Turner, et al. "Primary Analysis Results from an Open-Label Phase II Study of INCB039110, a Selective JAK1 Inhibitor, in Patients with Myelofibrosis." Blood 124, no. 21 (December 6, 2014): 714. http://dx.doi.org/10.1182/blood.v124.21.714.714.
Full textKutsch, Nadine, Christian Pallasch, Eugen Tausch, Volkmar Boehme, Matthias Ritgen, Ruediger Liersch, Alexander Wacker, et al. "A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Entospletinib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)." Blood 134, Supplement_1 (November 13, 2019): 4297. http://dx.doi.org/10.1182/blood-2019-130912.
Full textGhobrial, Irene M., Jean-Luc Harousseau, Steven P. Treon, Brianna Harris, Courtney E. Lin, Zheng Yuan, Karim Benhadji, James E. Wooldridge, and Veronique Leblond. "Enzastaurin in Previously Treated Waldenstrom's Macroglobulinemia: An Open-Label, Multicenter, Phase II Study." Blood 114, no. 22 (November 20, 2009): 3867. http://dx.doi.org/10.1182/blood.v114.22.3867.3867.
Full textWitzig, Thomas E., Lubomir Sokol, Francine M. Foss, Won-Seog Kim, Eric Jacobsen, Maria de Fatima De La Cruz, Dolores Caballero, et al. "Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study." Blood 134, Supplement_1 (November 13, 2019): 468. http://dx.doi.org/10.1182/blood-2019-128513.
Full textSpencer, Andrew, Simon Harrison, Jacob P. Laubach, Jeffrey Zonder, Ashraf Z. Badros, Krystal Bergin, Amit Khot, et al. "Pmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study." Blood 128, no. 22 (December 2, 2016): 3326. http://dx.doi.org/10.1182/blood.v128.22.3326.3326.
Full textHillmen, Peter, John G. Gribben, George A. Follows, Donald Milligan, Hazem A. Sayala, Paul Moreton, David G. Oscier, et al. "Rituximab Plus Chlorambucil In Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CLL): Final Response Analysis of An Open-Label Phase II Study." Blood 116, no. 21 (November 19, 2010): 697. http://dx.doi.org/10.1182/blood.v116.21.697.697.
Full textIyer, Swami P., Auris Huen, Bradley Haverkos, Weiyun Z. Ai, Craig Okada, Timothy M. Kuzel, Mary Jo Lechowicz, et al. "A Multi-Center, Open Label, Phase I/II Study to Assess the Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma." Blood 136, Supplement 1 (November 5, 2020): 8–10. http://dx.doi.org/10.1182/blood-2020-136018.
Full textBussel, James B., George R. Buchanan, David J. Gnarra, Richard H. Ho, Kun Nie, and Melissa Eisen. "Long-Term Use of Open-Label Romiplostim in Children with Chronic/Refractory Immune Thrombocytopenia (ITP)." Blood 120, no. 21 (November 16, 2012): 621. http://dx.doi.org/10.1182/blood.v120.21.621.621.
Full textGay, Francesca, Valeria Magarotto, Maria Teresa Petrucci, Francesco Di Raimondo, Luděk Pour, Tommaso Caravita, Vlastimil Scudla, et al. "Autologous Transplantation Versus Cyclophosphamide-Lenalidomide-Prednisone Followed By Lenalidomide-Prednisone Versus Lenalidomide Maintenance in Multiple Myeloma: Long-Term Results of a Phase III Trial." Blood 126, no. 23 (December 3, 2015): 392. http://dx.doi.org/10.1182/blood.v126.23.392.392.
Full textGotlib, Jason, Nashat Gabrail, Casey L. O'Connell, Regina Garcia-Delgado, Timothy Sbardellati, Wayne M. Rothbaum, Jesse McGreivy, Claire N. Harrison, and Jean-Jacques Kiladjian. "A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera." Blood 134, Supplement_1 (November 13, 2019): 4168. http://dx.doi.org/10.1182/blood-2019-123546.
Full textBurke, John M., Marc André, Bruce D. Cheson, Johannes Duell, Grzegorz Nowakowski, Andreas Rosenwald, Gilles A. Salles, et al. "A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial." Blood 134, Supplement_1 (November 13, 2019): 2877. http://dx.doi.org/10.1182/blood-2019-128021.
Full textZelenetz, Andrew D., Pier Luigi Luigi Zinzani, Henry Chan, Christian Buske, Vincent Ribrag, David Cunningham, Wojciech Jurczak, et al. "ME-401-003 (TIDAL): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 Investigating Continuous and Intermittent Dosing Schedules in Patients with Relapsed/Refractory Follicular Lymphoma." Blood 134, Supplement_1 (November 13, 2019): 5244. http://dx.doi.org/10.1182/blood-2019-124326.
Full textEscobar, Miguel A., Amy Dunn, Doris Quon, Ben Trzaskoma, Lucy Lee, Richard H. Ko, and Shannon L. Carpenter. "A Phase IV, Multicenter, Open-Label Study of Emicizumab Prophylaxis in Persons with Hemophilia a with or without FVIII Inhibitors Undergoing Minor Surgical Procedures." Blood 136, Supplement 1 (November 5, 2020): 30–31. http://dx.doi.org/10.1182/blood-2020-134906.
Full textRichardson, Paul G., David Siegel, Rachid Baz, Susan L. Kelley, Nikhil C. Munshi, Daniel Sullivan, Melissa Alsina, et al. "A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or In Combination with Low-Dose Dexamethasone In Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib." Blood 116, no. 21 (November 19, 2010): 864. http://dx.doi.org/10.1182/blood.v116.21.864.864.
Full textRaje, Noopur, Paul Richardson, Parameswaran N. Hari, Anuj Mahindra, Sarah Kaster, Christine Connolly, Linda Rivera, et al. "An Open-Label Phase I Study of the Safety and Efficacy of RAD001 in Combination with Lenalidomide in the Treatment of Patients with Relapsed and Relapsed/Refractory Multiple Myeloma." Blood 114, no. 22 (November 20, 2009): 3856. http://dx.doi.org/10.1182/blood.v114.22.3856.3856.
Full text